Yoon J, Lee CK, Kim JW, Kang B, et al. Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. J Hepatol 2025 Nov 24:S0168-8278(25)02626-1. doi: 10.1016/j.jhep.2025.
PMID: 41297674